Literature DB >> 2439195

Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.

B E Antonsson, V I Avramis, J Nyce, J S Holcenberg.   

Abstract

The human lymphoid cell lines CCRF/CEM/0 and the deoxycytidine kinase (dCk)-deficient CCRF/CEM/dCk- were treated with various 5-azacytidine (5-aza-C) nucleosides and the effect on DNA methylation and dCk activity were examined. 5-Azacytidine (5-aza-C), 5,6-dihydro-5-azacytidine (DHAC), 5-aza-2'-deoxycytidine (5-aza-Cdr), and 1-beta-D-arabinofuranosyl-5-azacytidine (ara-AC) reduced the DNA 5-methylcytosine level in the CEM/0 cells, down to approximately 10% of the level in untreated cells. The dCk activity was increased after treatment with the 5-aza-C nucleosides approximately 10% compared to untreated cells. In CEM/dCk- cells DNA hypomethylation between 50 and 25% of control was seen only after treatment with DHAC and 5-aza-C. No decrease in the methylation level was seen after treatment with 5-aza-Cdr or ara-AC. The dCk activity was increased up to 37% after treatment with DHAC or 5-aza-C but no increase was observed after treatment with 5-aza-Cdr or ara-AC. CEM/dCk- cells treated with DHAC showed a revertant frequency to cells expressing dCk activity of between 0.1 and 0.6%. Cloned revertant CEM/dCk- cells isolated from soft agar had dCk activity between 31 and 113% compared to the activity in untreated CEM/0 cells. This in vitro study indicates that DHAC and 5-aza-C induced dCk re-expression in the CEM/dCk- cells whereas 5-aza-Cdr and ara-AC did not.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439195

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

2.  Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.

Authors:  V I Avramis; R A Mecum; J Nyce; D A Steele; J S Holcenberg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential.

Authors:  M H Jiang; J Fei; M S Lan; Z P Lu; M Liu; W W Fan; X Gao; D R Lu
Journal:  Diabetologia       Date:  2008-05-22       Impact factor: 10.122

6.  Biochemical pharmacology of 5,6-dihydro-5-azacytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice.

Authors:  W C Powell; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.

Authors:  V I Avramis; W C Powell; R A Mecum
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.

Authors:  Myrna Candelaria; Erick de la Cruz-Hernandez; Lucia Taja-Chayeb; Enrique Perez-Cardenas; Catalina Trejo-Becerril; Aurora Gonzalez-Fierro; Alma Chavez-Blanco; Ernesto Soto-Reyes; Guadalupe Dominguez; Jaenai E Trujillo; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 9.  The quest for an effective and safe personalized cell therapy using epigenetic tools.

Authors:  T A L Brevini; G Pennarossa; E F M Manzoni; C E Gandolfi; A Zenobi; F Gandolfi
Journal:  Clin Epigenetics       Date:  2016-11-16       Impact factor: 6.551

10.  Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers.

Authors:  David W Chan; Wai-Yip Lam; Fushun Chen; Mingo M H Yung; Yau-Sang Chan; Wai-Sun Chan; Fangfang He; Stephanie S Liu; Karen K L Chan; Benjamin Li; Hextan Y S Ngan
Journal:  Clin Epigenetics       Date:  2021-07-22       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.